# Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

> **NCT04446000** · PHASE1 · TERMINATED · sponsor: **CSL Behring** · enrollment: 52 (actual)

## Conditions studied

- Immune Complex-mediated Autoimmune Diseases

## Interventions

- **BIOLOGICAL:** CSL730
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04446000
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-23
- **Primary completion:** 2023-03-28
- **Final completion:** 2023-03-28
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Lack of clinical viability
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04446000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04446000, "Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04446000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*